nach oben

Journal of Cutaneous Medicine and Surgery

Erschienen in:

01.12.2005

A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence

Erschienen in: Journal of Cutaneous Medicine and Surgery | Sonderheft 1/2005

Einloggen, um Zugang zu erhalten

Abstract

Moderate to severe plaque psoriasis has traditionally been treated with agents that have toxicities associated with long-term use. Many patients therefore cannot be treated safely, conveniently or effectively with traditional therapies. Recent phase 3 clinical trials for efalizumab, a biological agent targeted specifically at the T-cell-based pathology of psoriasis, have demonstrated its short- and long-term efficacy and safety for the treatment of psoriasis. This article reviews results from 12-week, six-month, and three-year trials, focusing on the drug’s safety, efficacy, and therapeutic response time, as well as the phenomenon of rebound in non-responding patients. Efalizumab emerges as an important addition to the dermatological pharmacopeia for the long-term treatment of psoriasis.

The static Physician’s Global Assessment (sPGA) evaluates disease severity at a single point in time. Values are assigned between 0-6 based on definitions clear, minimal, mild, moderate, severe or very severe, respectively.

Cather JC, Menter A. Efalizumab: Continuous therapy for chronic psoriasis. Expert Opin Biol Ther 2005; 5(3):393–403PubMedCrossRef

Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004; 22:427–435PubMedCrossRef

Wellington K, Perry CM. Efalizumab. Am J Clin Dermatol 2005; 6(2):113–118PubMedCrossRef

Cather JC, Cather JC, Menter A. Modulating T–cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003; 3(2):361–370PubMedCrossRef

Della Croce C, Kwan Wong V, Lebwohl MG. Efalizumab in the treatment of psoriasis. Therapy 2004; 1(2):197–202CrossRef

Shear NH, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2005; This supplement

Raptiva® (efalizumab) Canadian Prescribing Information. Serono Canada, Inc. 2005

Papp KA, Toth DP. Safety and efficacy of efalizumab retreatment: Final results from an open-label study in psoriasis. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17–21, 2004; Florence, Italy. Poster #74

Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003; 49:S98–104. PubMedCrossRef

10.

Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis. JAMA 2003; 290:3073–3080PubMedCrossRef

11.

Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004; 3(6):614–624PubMed

12.

Gottlieb A, Gordon K, Hamilton T, et al. Maintenance of Efficacy and Safety with Continuous Efalizumab Therapy in Patients with Moderate to Severe Chronic Plaque Psoriasis: Final Phase IIIb Study Results. Presented at the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans; 2005. Poster #4

13.

Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell moderator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004–2013PubMedCrossRef

14.

Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141:31–38PubMedCrossRef

15.

Leonardi CL, Papp KA, Gordon KB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52:425–433PubMedCrossRef

16.

Sterry W, Dubertret L, Papp K, et al. Efalizumab for patients with moderate to severe chronic plaque psoriasis: Results of the international, randomized, controlled phase III Clinical Experience Raptiva (CLEAR) trial. Presented at the 34th Annual ESDR Meeting. September 9–11, 2004. Vienna, Austria. Poster #386

17.

Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50:859–866PubMedCrossRef

18.

Stone S, Papp KA, Caro I, et al. Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17–21, 2004; Florence, Italy. Poster #610.

19.

Menter A, Kardatzke D, Rundle AC et al. Incidence and prevention of rebound upon efalizumab discontinuation. Poster presentation at the 11th International Psoriasis Symposium. June 15–18, 2005; Toronto, Canada

20.

Papp KA, Toth D, Rosolph L. Approaches to discontinuing efalizumab: Results of an open-label study comparing different transitioning therapies. Presented at the 3rd European Academy of Dermatology and Venereology Spring Symposium, Sofia, Bulgaria, May 19–22, 2005. Poster #PDT9

21.

Carey W, Rundle AC, Kwon P, Leonardi CL. Taper regimens in the management of patients discontinuing efalizumab therapy. Presented at the 11th International Psoriasis Symposium. June 14–19, 2004; Toronto, Canada. Poster #29

22.

Papp K. Patient management in psoriasis treatment using efalizumab. J Cutan Med Surg 2005; This supplement

23.

Carey W, Toth DP, Bissonnette R et al. No evidence for increased risk of infection during efalizumab treatment: A review of the clinical data. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17–21, 2004; Florence, Italy. Poster #79

24.

Toth DP, Carey W, Bissonnette R et al. Risk of malignancy during efalizumab treatment: A review of the clinical data. Presented at the 13th Congress of the European Academy of Dermatology and Venereology. November 17–21, 2004; Florence, Italy. Poster #110

Titel: A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence
Publikationsdatum: 01.12.2005
Erschienen in: Journal of Cutaneous Medicine and Surgery / Ausgabe Sonderheft 1/2005
Print ISSN: 1203-4754
Elektronische ISSN: 1615-7109
DOI: https://doi.org/10.1007/s10227-006-0102-2

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2005

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis

Efalizumab, a reversible T-cell modulator for psoriasis

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches